Affymax AFFY

  1. All
  2. Commentary
  3. Headlines
    1. Affymax may consider filing for bankruptcy; cuts workforce by 75 percent


      Mon, 18 Mar 2013

      (Reuters) - Drug maker Affymax Inc said it may consider selling itself or filing for bankruptcy among a range of strategic alternatives as it struggles with the recent recall of its sole commercial product, the anemia drug Omontys.

    2. Affymax may consider filing for bankruptcy; cuts workforce by 75 pct


      Mon, 18 Mar 2013

      March 18 (Reuters) - Affymax Inc, which recalled its anemia drug Omontys in February, said it may consider selling itself or filing for bankruptcy among a range of strategic alternatives.

    3. Affymax stock plunges 85 percent on drug recall


      Mon, 25 Feb 2013

      (Reuters) - Shares of Affymax Inc fell 85 percent after it said serious adverse reactions, including death, were reported among some of those using its sole commercial product, anemia drug Omontys.

    4. Amgen's Enbrel Sees Outstanding 2012, but Neulasta Worries Keep Our Long-Term Forecast Conservative


      Thu, 24 Jan 2013

      Aranesp pressure was expected, and Epogen declines appear to be caused more by competition (albeit minimal) from Affymax 's AFFY Omontys and less from the decreased ESA usage due to bundled reimbursement that has plagued growth in previous quarters

    5. No Surprises in Amgen's First Quarter; Raising Our Fair Value Estimate on Pipeline Progress


      Tue, 24 Apr 2012

      operators DaVita DVA and Fresenius FMS, we think future biosimilar competition--as well as branded products like Affymax 's AFFY recently approved anemia drug Omontys--cloud Epogen's long-term prospects. We're forecasting continued double

    6. Amgen's Micromet Acquisition and Strong 2012 Outlook Are Positives, but Shares Look Fairly Valued


      Thu, 26 Jan 2012

      sign for near-term sales. However, the DaVita deal only covers one third of the U.S. dialysis market, and Affymax 's AFFY Hematide--a more convenient and potentially cheaper option in a price-sensitive market--could receive Food

    7. Dropping Coverage of Affymax


      Mon, 11 Oct 2010

      We are dropping coverage of Affymax AFFY to focus our resources elsewhere.

    8. Affymax Updates Hematide Approval Plan


      Thu, 5 Aug 2010

      Affymax AFFY and partner Takeda announced Thursday their preliminary strategy toward ..... keeping our fair value estimate in place until we hear details regarding Affymax 's meeting with the FDA . As a reminder , the frequency of cardiovascular

    9. Lowering Affymax's Fair Value


      Mon, 28 Jun 2010

      lowering our fair value estimate for Affymax AFFY following the release of clinical ..... cardiovascular concerns), and we now think Affymax 's chances of winning approval ..... market for predialysis, we think Affymax and partner Takeda will need to

    10. Affymax's Hematide Data Fall Short


      Mon, 21 Jun 2010

      Affymax AFFY and its partner Takeda released data from ..... transfusions than in the Aranesp arm. Affymax management is still assessing the timing ..... scenario would leave little left to value in Affymax , and our fair value estimate would approach

    « Prev12Next »
    Content Partners